TENAX THERAPEUTICS, INC. (TENX) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, TENAX THERAPEUTICS, INC.'s filing signal turned negative.

Tenax Therapeutics is a clinical-stage pharmaceutical company focused on developing novel cardiopulmonary therapies, leveraging a clinician-driven approach to target disease pathophysiology. The company is advancing oral levosimendan through two Phase 3 clinical trials, LEVEL and LEVEL-2, for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), a condition with no currently approved treatments. Levosimendan, an already approved drug in other indications, is being developed with a focus on its vasodilatory properties. Tenax also has imatinib as a potential therapy for pulmonary arterial hypertension (PAH) but has deprioritized its Phase 3 development to focus on levosimendan. The company aims to submit marketing authorization applications for levosimendan following the completion of its Phase 3 trials.

The company currently has no approved drug products for sale and generates no revenue. Future revenue is expected to be driven by the successful development and commercialization of its product candidates, primarily levosimendan.